For the Inventor, By the Inventor

Enter assignee name

Frankfurt, Germany

Asta Pharma Aktiengesellschaft

Calculating rank

USPTO Granted Patents = 29

Forward Citations = 390

Loading Chart...

Loading Chart...

54 inventors (with patents filed for the assignee):

Jurgen Engel (12 out of 81 patents)

Helmut Hettche (10 out of 25 patents)

Gerhard Scheffler (6 out of 18 patents)

4. Wolfgang Morick (4 out of 4 patents)

5. Ilona Fleischhauer (4 out of 9 patents)

6. Reinhard Muckenschnabel (4 out of 6 patents)

7. Dieter Sauerbier (4 out of 18 patents)

8. Istvan Szelenyi (3 out of 33 patents)

9. Bernd Nickel (3 out of 27 patents)

10. Wolfgang Schumacher (3 out of 9 patents)

11. Peter Hilgard (3 out of 17 patents)

12. Heinz Ulrich (3 out of 13 patents)

13. Carl-Heinrich Weischer (3 out of 5 patents)

14. Rainer Voegeli (3 out of 4 patents)

15. Peter Emig (2 out of 29 patents)

Core Competencies:

Azelastine

R-Α-Lipoic Acid

Controlled Release

Pharmaceutical Composition

Psoriasis Treatment

Diamine-Platinum Complexes

Pain Management

Heterocyclic Compounds

Medicinal Formulations

Stability Solutions

Ifosfamide

Synergistic Combinations

29 patents: Sort by Forward Citations

1. 6271254 - Pharmaceutical compositions containing R-&agr;-lipoic acid or S-&agr;-lipoic acid as active ingredient (2001-08-07),

2. 6017909 - Salts of azelastine having improved solubility effective at treating (2000-01-25),

3. 5998403 - Salts of azelastine having improved solubility useful at providing a (1999-12-07),

4. 5859003 - Salts of azelastine having improved solubility (1999-01-12),

5. 5728735 - Pharmaceutical composition containing R-.alpha.-lipoic acid or (1998-03-17),

6. 5334612 - Pharmaceutical compositions containing as active substance (1994-08-02),

7. 5290769 - Use of hexadecylphosphocholine for the treatment of psoriasis (1994-03-01),

8. 5271946 - Controlled release azelastine-containing pharmaceutical compositions (1993-12-21),

9. 5238955 - Ethylene-substituted phenylalkylethylenediamine-platinum (II or IV) (1993-08-24),

10. 5232919 - Azelastine embonate and compositions which contain it (1993-08-03),

11. 5204335 - Ifosfamide lyophilisate and process for its preparation (1993-04-20),

12. 5194644 - Ethylene-substituted phenylalkylethylene-diamine-platinum (II or IV) (1993-03-16),

13. 5164194 - Azelastine containing medicaments (1992-11-17),

14. 5110814 - Azelastine and its salts used to combat psoriasis (1992-05-05),

15. 5086050 - Method of treating inflammatory disorders and psoriasis with salts of (1992-02-04),

Company Overview

Asta Pharma Aktiengesellschaft is a prominent player in the pharmaceutical sector, specializing in the development and manufacturing of high-quality medicinal products. The company focuses on areas such as ophthalmology, dermatology, and other therapeutic domains, emphasizing innovative solutions to enhance patient care. Based in Frankfurt, Germany, Asta Pharma is committed to advancing healthcare through rigorous research and development, ensuring that its offerings meet the evolving needs of the medical community and patients alike.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

29 Patents

#36 in Frankfurt

#1,655 in Germany

#22,595 in the World

Frankfurt, Germany

Asta Pharma Aktiengesellschaft

Forward Citations = 390

54 inventors:

Jurgen Engel (12 out of 81 patents)

Helmut Hettche (10 out of 25 patents)

Gerhard Scheffler (6 out of 18 patents)

4. Wolfgang Morick (4 out of 4 patents)

5. Ilona Fleischhauer (4 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Asta Pharma Aktiengesellschaft. Retrieved from https://idiyas.com/company/asta-pharma-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…